GlassScriptPhysician profile
Regina J Wang
NPI 1073504643
$24,583.78
in general payments reported to CMS, 2019-2025
53 companies · $3,192 in 2025
The $3,192 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,852 · 2020: $2,882 · 2021: $5,447 · 2022: $3,542 · 2023: $2,781 · 2024: $2,889 · 2025: $3,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,812 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,811.97 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,818.73 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $2,939.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $2,122.35 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Biohaven Pharmaceuticals, INC. | $1,825.40 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,743.82 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $1,195.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $814.61 | 2019-2025 | Livdelzi, Vemlidy |
| Amarin Pharma, INC. | $807.75 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $804.51 | 2019-2023 | |
| Eisai INC. | $645.78 | 2020-2024 | |
| Pfizer INC. | $621.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $411.94 | 2021-2025 | Arexvy, Shingrix, Boostrix |
| Abbott Laboratories | $395.95 | 2021-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $395.02 | 2022-2025 | Korlym |
| Lundbeck LLC | $389.12 | 2022-2025 | Vyepti, Rexulti |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.